Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

Marilyn K. Glassberg, Steven D. Nathan, Chin Yu Lin, Elizabeth A. Morgenthien, John L. Stauffer, Willis Chou, Paul W. Noble

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Fingerprint

Dive into the research topics of 'Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis'. Together they form a unique fingerprint.

Medicine & Life Sciences